Schellenberg Wittmer advised Bioventure Club Deal Nine & Co KG in a Series C financing round of the Swiss Aphaia companies, which are clinical-stage pharmaceutical companies that have developed proprietary treatment methods targeting obesity and
Schellenberg Wittmer advised Bioventure Club Deal Nine & Co KG in a Series C financing round of the Swiss Aphaia companies, which are clinical-stage pharmaceutical companies that have developed proprietary treatment methods targeting obesity and